RecruitingNot ApplicableNCT06075940

Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold in the Treatment of Patients With Below the Knee Disease in Australia

Evaluation of the MAGNITUDE® Bioresorbable Drug-Eluting Scaffold (BRS)in the Treatment of Patients With Below the Knee Disease in Australia

Sponsor

R3 Vascular Inc.

Enrollment

30 participants

Start Date

Mar 4, 2024

Study Type

INTERVENTIONAL

Conditions

Critical Lower Limb Ischemia Critical Limb-Threatening Ischemia Critical Limb Ischemia

Summary

The objective of this prospective, multi-center, clinical investigation is to evaluate the MAGNITUDE BRS System for the planned treatment of narrowed infrapopliteal lesions. Up to 30 subjects will be enrolled at approximately 3 clinical sites in Australia.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called MAGNITUDE BRS for people with critical limb ischemia, critical limb-threatening ischemia, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.